BRIGHT .: Best-in-class RapId companion diaGnostics cHip for cancer stratification

Title: BRIGHT .: Best-in-class RapId companion diaGnostics cHip for cancer stratification

Project code: NORTE-01-0247-FEDER-072328

Main goal: Reinforce research, technological development and innovation

Intervention region: Norte

Beneficiary entity: RUBYnanomed, Lda

Approval date: 29-07-2021

Start Date: 01-07-2021

End Date: 30-06-2023

Project Total Eligible Budget: 1 904 978,04 €

FEDER Funding: 1 193 347,72€

Project Description Metastasis is the responsible of 90% of cancer related deaths, caused by the migration of the so called circulating tumour cells (CTCs) via bloodstream, to other parts of the body.

RUBYnanomed has developed the RUBYchip, the first In Vitro Diagnostics (IVD) device that allows continuous monitoring of the metastasis evolution, allowing the fast-therapeutic efficiency evaluation and adjustment to the patient needs. The RUBYchip isolates and identifies CTCs with a remarkable efficiency of >70 %, way superior to any of the competing technologies, in less than 3 h.

With this project it is expected to develop the entire automation of a single processing and reading unit, ensuring the repeatability of the results, minimising inter-user and inter-laboratory variability and ultimately offering an all-in-one solution as-a-service to hospitals and laboratories at low cost. In the evolving worldwide scenario towards personalised medicine (3.18 trillion, 2025), the innovative RUBYchip is positioned to enter the market of IVD by 2023 and fill the gap of liquid biopsy for companion diagnostics (CDx; 7.64 bn by 2025) from 2025 onwards.